Myriad Genetics (MYGN) provided an update on its engagement with UnitedHealthcare (UNH) following the November 1 publication of its updated medical policy restricting access to multi-gene panel pharmacogenetic tests, including Myriad’s GeneSight test, under its commercial and individual exchange benefit plans, effective January 1, 2025. Since the announcement, Myriad has actively engaged in constructive dialogue with UNH regarding the clinical evidence supporting Myriad’s proprietary and clinically differentiated mental health medication test, GeneSight, including presenting additional clinical data to UnitedHealthcare for its further review and consideration. Myriad has requested that UHC enrollees continue to have access to the test in 2025, especially in the primary care setting where a significant majority of antidepressants are prescribed 1.During Myriad’s Q3 earnings call held on November 6, the company provided an estimate of the 2024 financial impact of UNH’s updated medical policy. While Myriad continues to engage with UNH, the company reaffirms this estimate.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MYGN:
- Myriad Genetics’ portfolio elevated by updated NCCN prostate cancer guidelines
- Myriad Genetics initiated with a Neutral at UBS
- Myriad announces its Prolaris test is still classified as ‘Advanced Tool’
- Leerink downgrades Myriad Genetics on reimbursement, competitive headwinds
- Myriad Genetics downgraded to Market Perform from Outperform at Leerink